Lantern Pharma is a clinical-stage oncology company developing cancer drugs using an AI-driven, biomarker-guided approach. Lantern's core strategy is "drug rescue" — in-licensing small molecule compounds that previously failed broad clinical trials, then using its proprietary AI platform, RADR, to identify specific patient subgroups likely to respond, and re-running targeted trials with biomarker-defined enrollment. Lantern also pursues de novo drug development guided by RADR's computational insights. The three lead drug candidates are LP-300, a rescued compound in a Phase 2 trial targeting never-smoker NSCLC patients who progressed after TKI therapy; LP-184, a synthetic lethal small molecule in Phase 1 across multiple solid tumor indications including TNBC, GBM, and pancreatic cancer, developed in part through a wholly owned subsidiary, Starlight Therapeutics; and LP-284, a stereoisomer of LP-184 in Phase 1 targeting relapsed/refractory non-Hodgkin's lymphoma. Lantern is pre-revenue and funds operations through equity raises, with a lean cost structure of roughly 23 employees and outsourced manufacturing. The company's monetization path relies on advancing programs to out-licensing inflection points with larger pharma partners, and separately commercializing RADR modules — including PredictBBB and withZeta.ai — to biopharma companies and researchers via subscriptions and access fees.